Background: Migraine is an acute non-communicable psychiatric disease, which causes many problems for affected patients,
creating defects in the life process of these individuals. This complication is often collaborative, and treatment of the participated
member can be an effective step to overcome the disturbances of migraines. This study aimed to evaluate the effect of atrifel on
patients with migraine headaches associated with gastrointestinal symptoms. Materials and Methods: This double blind randomized
clinical trial was conducted on 124 patients, August 2017 till July 2018, who referred to Neurology Clinic of Shahid Sadoughi
Hospital, Yazd, Iran. Patients were randomly and equally divided into control and intervention groups. While subjects of the control
group received a daily dose of sodium valproate 200 mg, the participants of the intervention group received both the mentioned
tablet and atrifel sagir 50 mg pill before lunch and dinner. The relevant parameters were measured before and eight weeks after the
intervention. Results: In this research, stress, fatigue, overeating, hearing loud voices, insomnia and consumption of high-calorie
foods were more involved in the emergence of migraine, compared to other factors. According to the results, the integrated use of
atrifel sagir and sodium valproate significantly reduced the severity of pain, duration of headache and the time required for rest
(P<0.001). Conclusion: According to the results of the study, atrifel sagir along with sodium valproate had considerable impacts on
reduction of severity of pain, duration of headache and time required for rest in patients.
Keywords: Migraine, Participatory Gastric Headache, Atrifel Sagir, Valproate